Diazoxide detailed information

Diazoxide detailed information

Clinical data
Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	Oral, intravenous
ATC code	C02DA01 (WHO) V03AH01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Protein binding	90%
Metabolism	Hepatic oxidation and sulfate conjugation
Elimination half-life	21-45 hours
Excretion	Renal
Identifiers
IUPAC name 7-chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
CAS Number	364-98-7
PubChem CID	3019
DrugBank	APRD00914
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C8H7ClN2O2S
Molar mass	230.672 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Diazoxide is a potassium channel activator, which causes local relaxation in smooth muscle by increasing membrane permeability to potassium ions. This switches off voltage-gated calcium ion channels which inhibits the generation of an action potential.

It is used as a vasodilator in the treatment of acute hypertension, and also to decrease the secretion of insulin in disease states such as insulinoma (a tumor producing insulin).